nodes	percent_of_prediction	percent_of_DWPC	metapath
Quinapril—Lisinopril—systemic scleroderma	0.326	1	CrCtD
Quinapril—ACE—systemic scleroderma	0.181	1	CbGaD
Quinapril—ACE—Lisinopril—systemic scleroderma	0.0836	0.408	CbGbCtD
Quinapril—ACE—Captopril—systemic scleroderma	0.0626	0.306	CbGbCtD
Quinapril—Enalapril—Captopril—systemic scleroderma	0.0617	0.274	CrCrCtD
Quinapril—SLC15A1—Lisinopril—systemic scleroderma	0.0335	0.164	CbGbCtD
Quinapril—Moexipril—Lisinopril—systemic scleroderma	0.0251	0.112	CrCrCtD
Quinapril—SLC15A1—Captopril—systemic scleroderma	0.0251	0.123	CbGbCtD
Quinapril—Cilazapril—Lisinopril—systemic scleroderma	0.0217	0.0965	CrCrCtD
Quinapril—Spirapril—Lisinopril—systemic scleroderma	0.0217	0.0965	CrCrCtD
Quinapril—Trandolapril—Lisinopril—systemic scleroderma	0.0204	0.0905	CrCrCtD
Quinapril—Ramipril—Lisinopril—systemic scleroderma	0.0204	0.0905	CrCrCtD
Quinapril—Enalapril—Lisinopril—systemic scleroderma	0.0204	0.0905	CrCrCtD
Quinapril—Aspartame—Lisinopril—systemic scleroderma	0.0172	0.0766	CrCrCtD
Quinapril—Benazepril—Lisinopril—systemic scleroderma	0.0164	0.073	CrCrCtD
Quinapril—ACE—forelimb zeugopod—systemic scleroderma	0.00393	0.24	CbGeAlD
Quinapril—ACE—pulmonary artery—systemic scleroderma	0.00294	0.18	CbGeAlD
Quinapril—ACE—skeletal joint—systemic scleroderma	0.00261	0.159	CbGeAlD
Quinapril—ACE—umbilical vein—systemic scleroderma	0.00194	0.119	CbGeAlD
Quinapril—ACE—artery—systemic scleroderma	0.00109	0.0666	CbGeAlD
Quinapril—ACE—endothelium—systemic scleroderma	0.000922	0.0563	CbGeAlD
Quinapril—ACE—blood vessel—systemic scleroderma	0.00085	0.0519	CbGeAlD
Quinapril—SLC15A1—digestive system—systemic scleroderma	0.000439	0.0268	CbGeAlD
Quinapril—ACE—connective tissue—systemic scleroderma	0.000436	0.0266	CbGeAlD
Quinapril—ACE—smooth muscle tissue—systemic scleroderma	0.000399	0.0243	CbGeAlD
Quinapril—ACE—digestive system—systemic scleroderma	0.000315	0.0192	CbGeAlD
Quinapril—ACE—lung—systemic scleroderma	0.000263	0.0161	CbGeAlD
Quinapril—SLC15A2—lung—systemic scleroderma	0.000229	0.014	CbGeAlD
Quinapril—Perindopril—ACE—systemic scleroderma	0.000206	0.128	CrCbGaD
Quinapril—Spirapril—ACE—systemic scleroderma	0.000203	0.126	CrCbGaD
Quinapril—Moexipril—ACE—systemic scleroderma	0.000195	0.121	CrCbGaD
Quinapril—Lisinopril—ACE—systemic scleroderma	0.000181	0.113	CrCbGaD
Quinapril—Cilazapril—ACE—systemic scleroderma	0.000181	0.113	CrCbGaD
Quinapril—Ramipril—ACE—systemic scleroderma	0.000176	0.109	CrCbGaD
Quinapril—Trandolapril—ACE—systemic scleroderma	0.000176	0.109	CrCbGaD
Quinapril—Benazepril—ACE—systemic scleroderma	0.000158	0.098	CrCbGaD
Quinapril—Enalapril—ACE—systemic scleroderma	0.000133	0.0827	CrCbGaD
Quinapril—Myalgia—Lisinopril—systemic scleroderma	5.71e-05	0.00126	CcSEcCtD
Quinapril—Chest pain—Lisinopril—systemic scleroderma	5.71e-05	0.00126	CcSEcCtD
Quinapril—Arthralgia—Lisinopril—systemic scleroderma	5.71e-05	0.00126	CcSEcCtD
Quinapril—Nervousness—Mycophenolate mofetil—systemic scleroderma	5.71e-05	0.00126	CcSEcCtD
Quinapril—Back pain—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.00125	CcSEcCtD
Quinapril—Dyspnoea—Leflunomide—systemic scleroderma	5.68e-05	0.00125	CcSEcCtD
Quinapril—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	5.67e-05	0.00125	CcSEcCtD
Quinapril—Discomfort—Lisinopril—systemic scleroderma	5.64e-05	0.00125	CcSEcCtD
Quinapril—Cerebrovascular accident—Methotrexate—systemic scleroderma	5.64e-05	0.00125	CcSEcCtD
Quinapril—Dyspepsia—Leflunomide—systemic scleroderma	5.61e-05	0.00124	CcSEcCtD
Quinapril—Pancreatitis—Prednisone—systemic scleroderma	5.61e-05	0.00124	CcSEcCtD
Quinapril—Vomiting—Mometasone—systemic scleroderma	5.6e-05	0.00124	CcSEcCtD
Quinapril—Dry mouth—Lisinopril—systemic scleroderma	5.58e-05	0.00123	CcSEcCtD
Quinapril—Sweating increased—Prednisone—systemic scleroderma	5.57e-05	0.00123	CcSEcCtD
Quinapril—Feeling abnormal—Azathioprine—systemic scleroderma	5.56e-05	0.00123	CcSEcCtD
Quinapril—Rash—Mometasone—systemic scleroderma	5.55e-05	0.00123	CcSEcCtD
Quinapril—Asthenia—Captopril—systemic scleroderma	5.55e-05	0.00122	CcSEcCtD
Quinapril—Dermatitis—Mometasone—systemic scleroderma	5.54e-05	0.00122	CcSEcCtD
Quinapril—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	5.54e-05	0.00122	CcSEcCtD
Quinapril—Gastrointestinal pain—Azathioprine—systemic scleroderma	5.52e-05	0.00122	CcSEcCtD
Quinapril—Headache—Mometasone—systemic scleroderma	5.51e-05	0.00122	CcSEcCtD
Quinapril—Gastrointestinal disorder—Leflunomide—systemic scleroderma	5.5e-05	0.00121	CcSEcCtD
Quinapril—Insomnia—Mycophenolic acid—systemic scleroderma	5.5e-05	0.00121	CcSEcCtD
Quinapril—Fatigue—Leflunomide—systemic scleroderma	5.49e-05	0.00121	CcSEcCtD
Quinapril—Oedema—Lisinopril—systemic scleroderma	5.47e-05	0.00121	CcSEcCtD
Quinapril—Anaphylactic shock—Lisinopril—systemic scleroderma	5.47e-05	0.00121	CcSEcCtD
Quinapril—Pruritus—Captopril—systemic scleroderma	5.47e-05	0.00121	CcSEcCtD
Quinapril—Paraesthesia—Mycophenolic acid—systemic scleroderma	5.46e-05	0.0012	CcSEcCtD
Quinapril—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	5.45e-05	0.0012	CcSEcCtD
Quinapril—Constipation—Leflunomide—systemic scleroderma	5.45e-05	0.0012	CcSEcCtD
Quinapril—Infection—Lisinopril—systemic scleroderma	5.44e-05	0.0012	CcSEcCtD
Quinapril—Dyspnoea—Mycophenolic acid—systemic scleroderma	5.42e-05	0.0012	CcSEcCtD
Quinapril—Somnolence—Mycophenolic acid—systemic scleroderma	5.4e-05	0.00119	CcSEcCtD
Quinapril—Shock—Lisinopril—systemic scleroderma	5.39e-05	0.00119	CcSEcCtD
Quinapril—Angioedema—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.00119	CcSEcCtD
Quinapril—Thrombocytopenia—Lisinopril—systemic scleroderma	5.36e-05	0.00118	CcSEcCtD
Quinapril—Dyspepsia—Mycophenolic acid—systemic scleroderma	5.35e-05	0.00118	CcSEcCtD
Quinapril—Tachycardia—Lisinopril—systemic scleroderma	5.34e-05	0.00118	CcSEcCtD
Quinapril—Abdominal pain—Azathioprine—systemic scleroderma	5.33e-05	0.00118	CcSEcCtD
Quinapril—Skin disorder—Lisinopril—systemic scleroderma	5.32e-05	0.00117	CcSEcCtD
Quinapril—Malaise—Mycophenolate mofetil—systemic scleroderma	5.3e-05	0.00117	CcSEcCtD
Quinapril—Hyperhidrosis—Lisinopril—systemic scleroderma	5.29e-05	0.00117	CcSEcCtD
Quinapril—Diarrhoea—Captopril—systemic scleroderma	5.29e-05	0.00117	CcSEcCtD
Quinapril—Vertigo—Mycophenolate mofetil—systemic scleroderma	5.28e-05	0.00117	CcSEcCtD
Quinapril—Syncope—Mycophenolate mofetil—systemic scleroderma	5.27e-05	0.00116	CcSEcCtD
Quinapril—Erectile dysfunction—Prednisone—systemic scleroderma	5.27e-05	0.00116	CcSEcCtD
Quinapril—Feeling abnormal—Leflunomide—systemic scleroderma	5.25e-05	0.00116	CcSEcCtD
Quinapril—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	5.25e-05	0.00116	CcSEcCtD
Quinapril—Fatigue—Mycophenolic acid—systemic scleroderma	5.24e-05	0.00116	CcSEcCtD
Quinapril—Nausea—Mometasone—systemic scleroderma	5.23e-05	0.00115	CcSEcCtD
Quinapril—Gastrointestinal pain—Leflunomide—systemic scleroderma	5.21e-05	0.00115	CcSEcCtD
Quinapril—Constipation—Mycophenolic acid—systemic scleroderma	5.2e-05	0.00115	CcSEcCtD
Quinapril—Palpitations—Mycophenolate mofetil—systemic scleroderma	5.19e-05	0.00115	CcSEcCtD
Quinapril—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	5.17e-05	0.00114	CcSEcCtD
Quinapril—Cough—Mycophenolate mofetil—systemic scleroderma	5.13e-05	0.00113	CcSEcCtD
Quinapril—Dizziness—Captopril—systemic scleroderma	5.11e-05	0.00113	CcSEcCtD
Quinapril—Liver function test abnormal—Methotrexate—systemic scleroderma	5.1e-05	0.00113	CcSEcCtD
Quinapril—Depression—Prednisone—systemic scleroderma	5.08e-05	0.00112	CcSEcCtD
Quinapril—Abdominal pain—Leflunomide—systemic scleroderma	5.04e-05	0.00111	CcSEcCtD
Quinapril—Acute coronary syndrome—Prednisone—systemic scleroderma	5.02e-05	0.00111	CcSEcCtD
Quinapril—Feeling abnormal—Mycophenolic acid—systemic scleroderma	5.01e-05	0.00111	CcSEcCtD
Quinapril—Myalgia—Mycophenolate mofetil—systemic scleroderma	5e-05	0.0011	CcSEcCtD
Quinapril—Chest pain—Mycophenolate mofetil—systemic scleroderma	5e-05	0.0011	CcSEcCtD
Quinapril—Arthralgia—Mycophenolate mofetil—systemic scleroderma	5e-05	0.0011	CcSEcCtD
Quinapril—Myocardial infarction—Prednisone—systemic scleroderma	5e-05	0.0011	CcSEcCtD
Quinapril—Breast disorder—Methotrexate—systemic scleroderma	5e-05	0.0011	CcSEcCtD
Quinapril—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	4.99e-05	0.0011	CcSEcCtD
Quinapril—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	4.97e-05	0.0011	CcSEcCtD
Quinapril—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.0011	CcSEcCtD
Quinapril—Insomnia—Lisinopril—systemic scleroderma	4.95e-05	0.00109	CcSEcCtD
Quinapril—Discomfort—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.00109	CcSEcCtD
Quinapril—Paraesthesia—Lisinopril—systemic scleroderma	4.92e-05	0.00109	CcSEcCtD
Quinapril—Vomiting—Captopril—systemic scleroderma	4.91e-05	0.00109	CcSEcCtD
Quinapril—Dry mouth—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.00108	CcSEcCtD
Quinapril—Dyspnoea—Lisinopril—systemic scleroderma	4.88e-05	0.00108	CcSEcCtD
Quinapril—Rash—Captopril—systemic scleroderma	4.87e-05	0.00108	CcSEcCtD
Quinapril—Dermatitis—Captopril—systemic scleroderma	4.87e-05	0.00107	CcSEcCtD
Quinapril—Somnolence—Lisinopril—systemic scleroderma	4.87e-05	0.00107	CcSEcCtD
Quinapril—Headache—Captopril—systemic scleroderma	4.84e-05	0.00107	CcSEcCtD
Quinapril—Dyspepsia—Lisinopril—systemic scleroderma	4.82e-05	0.00106	CcSEcCtD
Quinapril—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.8e-05	0.00106	CcSEcCtD
Quinapril—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.8e-05	0.00106	CcSEcCtD
Quinapril—Oedema—Mycophenolate mofetil—systemic scleroderma	4.8e-05	0.00106	CcSEcCtD
Quinapril—Infection—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.00105	CcSEcCtD
Quinapril—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.73e-05	0.00104	CcSEcCtD
Quinapril—Fatigue—Lisinopril—systemic scleroderma	4.72e-05	0.00104	CcSEcCtD
Quinapril—Shock—Mycophenolate mofetil—systemic scleroderma	4.72e-05	0.00104	CcSEcCtD
Quinapril—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.7e-05	0.00104	CcSEcCtD
Quinapril—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.7e-05	0.00104	CcSEcCtD
Quinapril—Pancreatitis—Methotrexate—systemic scleroderma	4.68e-05	0.00103	CcSEcCtD
Quinapril—Constipation—Lisinopril—systemic scleroderma	4.68e-05	0.00103	CcSEcCtD
Quinapril—Tachycardia—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.00103	CcSEcCtD
Quinapril—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.66e-05	0.00103	CcSEcCtD
Quinapril—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.64e-05	0.00102	CcSEcCtD
Quinapril—Diarrhoea—Azathioprine—systemic scleroderma	4.62e-05	0.00102	CcSEcCtD
Quinapril—Nausea—Captopril—systemic scleroderma	4.59e-05	0.00101	CcSEcCtD
Quinapril—Asthenia—Leflunomide—systemic scleroderma	4.57e-05	0.00101	CcSEcCtD
Quinapril—Feeling abnormal—Lisinopril—systemic scleroderma	4.51e-05	0.000996	CcSEcCtD
Quinapril—Pruritus—Leflunomide—systemic scleroderma	4.51e-05	0.000995	CcSEcCtD
Quinapril—Connective tissue disorder—Prednisone—systemic scleroderma	4.5e-05	0.000993	CcSEcCtD
Quinapril—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.48e-05	0.000988	CcSEcCtD
Quinapril—Dizziness—Azathioprine—systemic scleroderma	4.46e-05	0.000985	CcSEcCtD
Quinapril—Erectile dysfunction—Methotrexate—systemic scleroderma	4.4e-05	0.000971	CcSEcCtD
Quinapril—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.37e-05	0.000965	CcSEcCtD
Quinapril—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.36e-05	0.000963	CcSEcCtD
Quinapril—Asthenia—Mycophenolic acid—systemic scleroderma	4.36e-05	0.000963	CcSEcCtD
Quinapril—Diarrhoea—Leflunomide—systemic scleroderma	4.36e-05	0.000962	CcSEcCtD
Quinapril—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000958	CcSEcCtD
Quinapril—Abdominal pain—Lisinopril—systemic scleroderma	4.33e-05	0.000955	CcSEcCtD
Quinapril—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000951	CcSEcCtD
Quinapril—Pruritus—Mycophenolic acid—systemic scleroderma	4.3e-05	0.000949	CcSEcCtD
Quinapril—Vomiting—Azathioprine—systemic scleroderma	4.29e-05	0.000947	CcSEcCtD
Quinapril—Eye disorder—Prednisone—systemic scleroderma	4.28e-05	0.000944	CcSEcCtD
Quinapril—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.28e-05	0.000944	CcSEcCtD
Quinapril—Somnolence—Mycophenolate mofetil—systemic scleroderma	4.26e-05	0.000941	CcSEcCtD
Quinapril—Infestation NOS—Methotrexate—systemic scleroderma	4.26e-05	0.000941	CcSEcCtD
Quinapril—Infestation—Methotrexate—systemic scleroderma	4.26e-05	0.000941	CcSEcCtD
Quinapril—Rash—Azathioprine—systemic scleroderma	4.25e-05	0.000939	CcSEcCtD
Quinapril—Dermatitis—Azathioprine—systemic scleroderma	4.25e-05	0.000938	CcSEcCtD
Quinapril—Depression—Methotrexate—systemic scleroderma	4.25e-05	0.000938	CcSEcCtD
Quinapril—Headache—Azathioprine—systemic scleroderma	4.23e-05	0.000933	CcSEcCtD
Quinapril—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.22e-05	0.000932	CcSEcCtD
Quinapril—Dizziness—Leflunomide—systemic scleroderma	4.21e-05	0.00093	CcSEcCtD
Quinapril—Renal failure—Methotrexate—systemic scleroderma	4.19e-05	0.000925	CcSEcCtD
Quinapril—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.16e-05	0.000918	CcSEcCtD
Quinapril—Angiopathy—Prednisone—systemic scleroderma	4.15e-05	0.000917	CcSEcCtD
Quinapril—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000914	CcSEcCtD
Quinapril—Immune system disorder—Prednisone—systemic scleroderma	4.13e-05	0.000913	CcSEcCtD
Quinapril—Constipation—Mycophenolate mofetil—systemic scleroderma	4.1e-05	0.000905	CcSEcCtD
Quinapril—Arrhythmia—Prednisone—systemic scleroderma	4.09e-05	0.000902	CcSEcCtD
Quinapril—Vomiting—Leflunomide—systemic scleroderma	4.05e-05	0.000894	CcSEcCtD
Quinapril—Alopecia—Prednisone—systemic scleroderma	4.04e-05	0.000893	CcSEcCtD
Quinapril—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.03e-05	0.000889	CcSEcCtD
Quinapril—Dizziness—Mycophenolic acid—systemic scleroderma	4.02e-05	0.000887	CcSEcCtD
Quinapril—Rash—Leflunomide—systemic scleroderma	4.02e-05	0.000887	CcSEcCtD
Quinapril—Dermatitis—Leflunomide—systemic scleroderma	4.01e-05	0.000886	CcSEcCtD
Quinapril—Mental disorder—Prednisone—systemic scleroderma	4.01e-05	0.000885	CcSEcCtD
Quinapril—Nausea—Azathioprine—systemic scleroderma	4.01e-05	0.000885	CcSEcCtD
Quinapril—Headache—Leflunomide—systemic scleroderma	3.99e-05	0.000881	CcSEcCtD
Quinapril—Agranulocytosis—Methotrexate—systemic scleroderma	3.98e-05	0.000878	CcSEcCtD
Quinapril—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.95e-05	0.000873	CcSEcCtD
Quinapril—Asthenia—Lisinopril—systemic scleroderma	3.93e-05	0.000867	CcSEcCtD
Quinapril—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.92e-05	0.000866	CcSEcCtD
Quinapril—Pruritus—Lisinopril—systemic scleroderma	3.87e-05	0.000855	CcSEcCtD
Quinapril—Vomiting—Mycophenolic acid—systemic scleroderma	3.86e-05	0.000853	CcSEcCtD
Quinapril—Rash—Mycophenolic acid—systemic scleroderma	3.83e-05	0.000846	CcSEcCtD
Quinapril—Dermatitis—Mycophenolic acid—systemic scleroderma	3.83e-05	0.000845	CcSEcCtD
Quinapril—Hepatitis—Methotrexate—systemic scleroderma	3.82e-05	0.000844	CcSEcCtD
Quinapril—Headache—Mycophenolic acid—systemic scleroderma	3.81e-05	0.000841	CcSEcCtD
Quinapril—Pharyngitis—Methotrexate—systemic scleroderma	3.8e-05	0.000838	CcSEcCtD
Quinapril—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.79e-05	0.000837	CcSEcCtD
Quinapril—Nausea—Leflunomide—systemic scleroderma	3.78e-05	0.000835	CcSEcCtD
Quinapril—Urinary tract disorder—Methotrexate—systemic scleroderma	3.78e-05	0.000834	CcSEcCtD
Quinapril—Urethral disorder—Methotrexate—systemic scleroderma	3.75e-05	0.000828	CcSEcCtD
Quinapril—Diarrhoea—Lisinopril—systemic scleroderma	3.75e-05	0.000827	CcSEcCtD
Quinapril—Ill-defined disorder—Prednisone—systemic scleroderma	3.7e-05	0.000816	CcSEcCtD
Quinapril—Angioedema—Prednisone—systemic scleroderma	3.64e-05	0.000804	CcSEcCtD
Quinapril—Dizziness—Lisinopril—systemic scleroderma	3.62e-05	0.000799	CcSEcCtD
Quinapril—Nausea—Mycophenolic acid—systemic scleroderma	3.61e-05	0.000797	CcSEcCtD
Quinapril—Malaise—Prednisone—systemic scleroderma	3.59e-05	0.000793	CcSEcCtD
Quinapril—Vertigo—Prednisone—systemic scleroderma	3.58e-05	0.00079	CcSEcCtD
Quinapril—Eye disorder—Methotrexate—systemic scleroderma	3.57e-05	0.000789	CcSEcCtD
Quinapril—Syncope—Prednisone—systemic scleroderma	3.57e-05	0.000789	CcSEcCtD
Quinapril—Cardiac disorder—Methotrexate—systemic scleroderma	3.55e-05	0.000784	CcSEcCtD
Quinapril—Loss of consciousness—Prednisone—systemic scleroderma	3.5e-05	0.000773	CcSEcCtD
Quinapril—Vomiting—Lisinopril—systemic scleroderma	3.48e-05	0.000768	CcSEcCtD
Quinapril—Angiopathy—Methotrexate—systemic scleroderma	3.47e-05	0.000766	CcSEcCtD
Quinapril—Immune system disorder—Methotrexate—systemic scleroderma	3.45e-05	0.000763	CcSEcCtD
Quinapril—Rash—Lisinopril—systemic scleroderma	3.45e-05	0.000762	CcSEcCtD
Quinapril—Dermatitis—Lisinopril—systemic scleroderma	3.45e-05	0.000761	CcSEcCtD
Quinapril—Mediastinal disorder—Methotrexate—systemic scleroderma	3.45e-05	0.000761	CcSEcCtD
Quinapril—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.44e-05	0.00076	CcSEcCtD
Quinapril—Headache—Lisinopril—systemic scleroderma	3.43e-05	0.000757	CcSEcCtD
Quinapril—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.39e-05	0.000749	CcSEcCtD
Quinapril—Arthralgia—Prednisone—systemic scleroderma	3.39e-05	0.000749	CcSEcCtD
Quinapril—Myalgia—Prednisone—systemic scleroderma	3.39e-05	0.000749	CcSEcCtD
Quinapril—Alopecia—Methotrexate—systemic scleroderma	3.38e-05	0.000746	CcSEcCtD
Quinapril—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.37e-05	0.000744	CcSEcCtD
Quinapril—Discomfort—Prednisone—systemic scleroderma	3.35e-05	0.00074	CcSEcCtD
Quinapril—Mental disorder—Methotrexate—systemic scleroderma	3.35e-05	0.00074	CcSEcCtD
Quinapril—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.28e-05	0.000724	CcSEcCtD
Quinapril—Nausea—Lisinopril—systemic scleroderma	3.25e-05	0.000718	CcSEcCtD
Quinapril—Anaphylactic shock—Prednisone—systemic scleroderma	3.25e-05	0.000718	CcSEcCtD
Quinapril—Oedema—Prednisone—systemic scleroderma	3.25e-05	0.000718	CcSEcCtD
Quinapril—Infection—Prednisone—systemic scleroderma	3.23e-05	0.000713	CcSEcCtD
Quinapril—Back pain—Methotrexate—systemic scleroderma	3.22e-05	0.000711	CcSEcCtD
Quinapril—Shock—Prednisone—systemic scleroderma	3.2e-05	0.000706	CcSEcCtD
Quinapril—Nervous system disorder—Prednisone—systemic scleroderma	3.19e-05	0.000704	CcSEcCtD
Quinapril—Tachycardia—Prednisone—systemic scleroderma	3.17e-05	0.000701	CcSEcCtD
Quinapril—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.17e-05	0.0007	CcSEcCtD
Quinapril—Skin disorder—Prednisone—systemic scleroderma	3.16e-05	0.000697	CcSEcCtD
Quinapril—Hyperhidrosis—Prednisone—systemic scleroderma	3.14e-05	0.000694	CcSEcCtD
Quinapril—Ill-defined disorder—Methotrexate—systemic scleroderma	3.09e-05	0.000682	CcSEcCtD
Quinapril—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000673	CcSEcCtD
Quinapril—Rash—Mycophenolate mofetil—systemic scleroderma	3.02e-05	0.000668	CcSEcCtD
Quinapril—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.02e-05	0.000667	CcSEcCtD
Quinapril—Headache—Mycophenolate mofetil—systemic scleroderma	3e-05	0.000663	CcSEcCtD
Quinapril—Malaise—Methotrexate—systemic scleroderma	3e-05	0.000663	CcSEcCtD
Quinapril—Vertigo—Methotrexate—systemic scleroderma	2.99e-05	0.00066	CcSEcCtD
Quinapril—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.96e-05	0.000654	CcSEcCtD
Quinapril—Insomnia—Prednisone—systemic scleroderma	2.94e-05	0.000649	CcSEcCtD
Quinapril—Paraesthesia—Prednisone—systemic scleroderma	2.92e-05	0.000644	CcSEcCtD
Quinapril—Cough—Methotrexate—systemic scleroderma	2.91e-05	0.000641	CcSEcCtD
Quinapril—Dyspepsia—Prednisone—systemic scleroderma	2.86e-05	0.000632	CcSEcCtD
Quinapril—Nausea—Mycophenolate mofetil—systemic scleroderma	2.85e-05	0.000629	CcSEcCtD
Quinapril—Myalgia—Methotrexate—systemic scleroderma	2.83e-05	0.000626	CcSEcCtD
Quinapril—Arthralgia—Methotrexate—systemic scleroderma	2.83e-05	0.000626	CcSEcCtD
Quinapril—Chest pain—Methotrexate—systemic scleroderma	2.83e-05	0.000626	CcSEcCtD
Quinapril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.81e-05	0.000621	CcSEcCtD
Quinapril—Fatigue—Prednisone—systemic scleroderma	2.8e-05	0.000619	CcSEcCtD
Quinapril—Discomfort—Methotrexate—systemic scleroderma	2.8e-05	0.000618	CcSEcCtD
Quinapril—Constipation—Prednisone—systemic scleroderma	2.78e-05	0.000614	CcSEcCtD
Quinapril—Anaphylactic shock—Methotrexate—systemic scleroderma	2.72e-05	0.0006	CcSEcCtD
Quinapril—Infection—Methotrexate—systemic scleroderma	2.7e-05	0.000596	CcSEcCtD
Quinapril—Feeling abnormal—Prednisone—systemic scleroderma	2.68e-05	0.000591	CcSEcCtD
Quinapril—Nervous system disorder—Methotrexate—systemic scleroderma	2.66e-05	0.000588	CcSEcCtD
Quinapril—Thrombocytopenia—Methotrexate—systemic scleroderma	2.66e-05	0.000587	CcSEcCtD
Quinapril—Gastrointestinal pain—Prednisone—systemic scleroderma	2.66e-05	0.000587	CcSEcCtD
Quinapril—Skin disorder—Methotrexate—systemic scleroderma	2.64e-05	0.000583	CcSEcCtD
Quinapril—Hyperhidrosis—Methotrexate—systemic scleroderma	2.63e-05	0.00058	CcSEcCtD
Quinapril—Abdominal pain—Prednisone—systemic scleroderma	2.57e-05	0.000567	CcSEcCtD
Quinapril—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.48e-05	0.000547	CcSEcCtD
Quinapril—Insomnia—Methotrexate—systemic scleroderma	2.46e-05	0.000543	CcSEcCtD
Quinapril—Paraesthesia—Methotrexate—systemic scleroderma	2.44e-05	0.000539	CcSEcCtD
Quinapril—Dyspnoea—Methotrexate—systemic scleroderma	2.42e-05	0.000535	CcSEcCtD
Quinapril—Somnolence—Methotrexate—systemic scleroderma	2.42e-05	0.000533	CcSEcCtD
Quinapril—Dyspepsia—Methotrexate—systemic scleroderma	2.39e-05	0.000528	CcSEcCtD
Quinapril—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.35e-05	0.000518	CcSEcCtD
Quinapril—Fatigue—Methotrexate—systemic scleroderma	2.34e-05	0.000517	CcSEcCtD
Quinapril—Asthenia—Prednisone—systemic scleroderma	2.33e-05	0.000515	CcSEcCtD
Quinapril—Pruritus—Prednisone—systemic scleroderma	2.3e-05	0.000508	CcSEcCtD
Quinapril—Feeling abnormal—Methotrexate—systemic scleroderma	2.24e-05	0.000494	CcSEcCtD
Quinapril—Diarrhoea—Prednisone—systemic scleroderma	2.22e-05	0.000491	CcSEcCtD
Quinapril—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.22e-05	0.000491	CcSEcCtD
Quinapril—Dizziness—Prednisone—systemic scleroderma	2.15e-05	0.000475	CcSEcCtD
Quinapril—Abdominal pain—Methotrexate—systemic scleroderma	2.15e-05	0.000474	CcSEcCtD
Quinapril—Vomiting—Prednisone—systemic scleroderma	2.07e-05	0.000456	CcSEcCtD
Quinapril—Rash—Prednisone—systemic scleroderma	2.05e-05	0.000453	CcSEcCtD
Quinapril—Dermatitis—Prednisone—systemic scleroderma	2.05e-05	0.000452	CcSEcCtD
Quinapril—Headache—Prednisone—systemic scleroderma	2.04e-05	0.00045	CcSEcCtD
Quinapril—Asthenia—Methotrexate—systemic scleroderma	1.95e-05	0.00043	CcSEcCtD
Quinapril—Nausea—Prednisone—systemic scleroderma	1.93e-05	0.000426	CcSEcCtD
Quinapril—Pruritus—Methotrexate—systemic scleroderma	1.92e-05	0.000424	CcSEcCtD
Quinapril—Diarrhoea—Methotrexate—systemic scleroderma	1.86e-05	0.00041	CcSEcCtD
Quinapril—Dizziness—Methotrexate—systemic scleroderma	1.8e-05	0.000397	CcSEcCtD
Quinapril—Vomiting—Methotrexate—systemic scleroderma	1.73e-05	0.000381	CcSEcCtD
Quinapril—Rash—Methotrexate—systemic scleroderma	1.71e-05	0.000378	CcSEcCtD
Quinapril—Dermatitis—Methotrexate—systemic scleroderma	1.71e-05	0.000378	CcSEcCtD
Quinapril—Headache—Methotrexate—systemic scleroderma	1.7e-05	0.000376	CcSEcCtD
Quinapril—Nausea—Methotrexate—systemic scleroderma	1.61e-05	0.000356	CcSEcCtD
